Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma

Status:	Active, not recruiting
Conditions:	Lymphoma
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - 80
Updated:	1/31/2019
Start Date:	October 2010
End Date:	May 2022

Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

This study will evaluate whether a reduction in the radiation dose and field size will
maintain a high rate of local control while minimizing the risk of acute and late toxicity.

Hypothesis- The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy
while maintaining high rates of local control in patients who had a negative PET scan
following rituximab-containing chemotherapy.

Inclusion Criteria:

- Histologic documentation of diffuse large B-cell lymphoma, or any of its variants as
defined in the WHO classification

- Completion of at least 4 cycles of a rituximab-containing, anthracycline-based
combination chemotherapy

- Negative post-chemotherapy (or interim) PET scan

- Absolute neutrophil count greater than 1500 and platelet count greater than 40,000

- Negative pregnancy test in women of child-bearing potential

For patients with HIV/AIDS, the following must be true:

- The patient is compliant on combination anti-retroviral therapy (CART)

- The patient has CD4 count ≥ 200 at time of diagnosis

Exclusion Criteria:

- Any contraindications to irradiation

- Primary CNS lymphoma

- HIV/AIDS

We found this trial at

sites

Durham Regional Hospital

Durham, North Carolina 27704

Principal Investigator: Bridget Koontz, MD

Phone: 919-470-8600

from

Durham, NC